Allena Pharmaceuticals

Allena Pharmaceuticals is a late-stage, clinical biopharmaceutical company focused on developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The company's key product candidate, ALLN-177, is an oral enzyme therapeutic that it is developing for the treatment of hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and pathophysiologically associated with kidney stones. The company's second product candidate, ALLN-346, is being developed for patients with hyperuricemia and moderate to severe chronic kidney disease.
  • TickerALNA
  • ISINUS0181191075
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for ALNA

ValuEngine Rating and Forecast Report for ALNA

Liana Moussatos ...
  • Shveta Dighe

Q1; Key Catalyst in H2- Top-line Data from Reloxaliase Phase 3 URIROX-1 Trial

ValuEngine Rating and Forecast Report for ALNA

ValuEngine Rating and Forecast Report for ALNA

Liana Moussatos ...
  • Shveta Dighe

Q1; Key Catalyst in H2- Top-line Data from Reloxaliase Phase 3 URIROX-1 Trial

ValuEngine Rating and Forecast Report for ALNA

ValuEngine Rating and Forecast Report for ALNA

ValuEngine Rating and Forecast Report for ALNA

ValuEngine Rating and Forecast Report for ALNA

ValuEngine Rating and Forecast Report for ALNA

ValuEngine Rating and Forecast Report for ALNA

ValuEngine Rating and Forecast Report for ALNA

ValuEngine Rating and Forecast Report for ALNA

ValuEngine Rating and Forecast Report for ALNA

ValuEngine Rating and Forecast Report for ALNA

ResearchPool Subscriptions

Get the most out of your insights

Get in touch